VP-001

DRUG3 trials

Sponsors

PYC Therapeutics

Conditions

Eye DiseasesEye Diseases HereditaryPRPF31 Mutationassociated Retinal DystrophyRP11Retinal DegenerationRetinal DiseaseRetinal DystrophiesRetinal Dystrophy

Phase 1

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

CompletedNCT05902962

PYC TherapeuticsPRPF31 Mutationassociated Retinal Dystrophy, Retinal Dystrophy, RP11

Start: 2023-04-20End: 2025-08-08Updated: 2026-05-29

MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)

CompletedNCT06455826

PYC TherapeuticsEye Diseases, Retinal Degeneration, Retinal Disease +2

Start: 2024-06-13End: 2025-09-24Updated: 2026-05-29

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

Active, not recruitingNCT06852963

PYC TherapeuticsEye Diseases Hereditary, Retinal Degeneration, Retinal Disease +2

Start: 2025-06-01End: 2028-04-21Updated: 2026-05-29